Eyevensys is a clinical stage, private, biotechnology company developing its innovative EyeCET platform to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic disease.

EyeCET stands for the eye ciliary muscle electro-transfection technology, which uses electroporation to deliver plasmids coding for therapeutic proteins in the eye. EyeCET is safe and non-viral, and it enables the ciliary muscle cells to sustainably produce therapeutic proteins locally. 

Eyevensys believes its EyeCET technology can improve short and long-term therapeutic outcomes, greatly enhancing patient compliance and significantly improve the tolerability of treatment. 

Eyevensys’ lead product EYS606 is a potential new treatment for patients with non-infectious Uveitis (NIU), the 4th cause of blindness in the world. 

EYS606 uses Eyevensys’ proprietary electro-transfection injection system (ETIS) to deliver a plasmid encoding for the production of an anti-TNF alpha-alpha cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in NIU. EYS606 which been granted an Orphan designation by the EMA for the treatment of NIU, has received in February 2017 the regulatory clearances from the UK MHRA and the French ANSM Health Agencies to begin a Phase I/II clinical trials. 

Subsequently, a multicentre clinical study has just been initiated in France and the UK.

Pontifax

Karista

Boehringer Ingelheim Venture Fund

Global health sciences venture fund

Inserm Transfert Initiative

Pureos Bioventures

Quark Venture

Bpifrance

Korea Investment Partners

EYEVENSYS

EYEVENSYS presented on the efficacy and durability of EYS809, a non-viral gene therapy for wet AMD, at Association for Research in Vision and Ophthalmology (ARVO) 2023 last week. Preclinical data showed greater reduction in both the incidence and area of leaky CNV lesions with EYS809 vs intravitreal aflibercept. The EYS809 dual plasmid is the first of its kind, resulting in production of the well-established anti-VEGF protein, aflibercept, as well as the promising novel candidate, decorin. Decorin has been found to play key roles in inhibiting angiogenic factors and regulating various pathways involved in retinal diseases, including the formation of CNV and RPE barrier breakdown. Studies are underway to assess how EYS809 limits subretinal fibrosis, and we look forward to further development of the program.



More information about the Eyevensys pipeline may be found here: https://lnkd.in/eHZnbybk

At #ARVO2023, EYEVENSYS shared exciting preclinical data demonstrating the superiority of our non-viral dual plasmid, EYS809, over intravitreal aflibercept in wet AMD. 

Please read the full release below. 







https://lnkd.in/ebix5Tej

Traveling to ARVO 2023? 

Join EYEVENSYS as we present exciting preclinical research on EYS809, our non-viral gene therapy candidate for the treatment of wet AMD.

More information about the meeting may be found via the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting website https://lnkd.in/gsPuQE7

EYEVENSYS CEO Patricia Zilliox, PhD, recently joined the Oracles of Eye Innovation Development of Drug Delivery Technology webinar to discuss Eyevensys’ innovative non-viral gene therapy platform. In the presentation, Patricia describes how the technology uses electrotransfection to non-invasively deliver plasmids to the eye, enabling the local production of therapeutic proteins for an extended period of time. Panelists agreed that the approach has transformative potential in the management of retinal diseases.

See the presentation here: https://lnkd.in/dZ3VHdhs



Presentation Topics
Introduction: 15:55
The Eyevensys platform: 16:25
Electrotransfection: 17:00
Current pipeline: 17:35
Therapeutic targets: 18:15
Clinical validation study: 19:05
Eyevensys Electrotransfection System demonstration: 19:45

Join Eyevensys for an in-depth discussion on ophthalmic drug delivery technology at the next Oracles of Eye Innovation webinar on February 14


Register here: https://lnkd.in/ebuSGwaj

.
.
.
https://lnkd.in/ewMCdymv

ONL Therapeutics is a biopharmaceutical company focused on developing novel therapies for the treatment of retinal diseases.

Ocular Therapeutix is a biopharmaceutical company that focuses on developing and commercializing innovative therapies for diseases and conditions of the eye.

Ocular

Aerpio Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for ocular diseases.

Aerpio

Eyevensys is a clinical-stage biotechnology company that specializes in first-in-class, non-viral vector gene therapy for treating major ophthalmic conditions, particularly degenerative retinal diseases and retinal vascular diseases such as wet AMD and dry AMD.

Eyevensys

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

network_onboarding

company_summary

regulatory_analysis

industry_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

swot_analysis

financial_analysis

news_advanced

purchaser_profile

news_impact_assignment_advanced

signals

news_processing_advanced

financial_statements

private_financials

funding_rounds_analysis

company_structure

crunchbase_trigger

crunchbase_profile

li_profile

translate_crunchbase_fundingrounds

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom
news impact assignment basic	general	Mar 5, 2024 10:37 AM	f004ca29
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 5, 2024 10:37 AM	159a37b7
company summary	general
news advanced	general
news impact assignment advanced	general
signals	general
news processing advanced	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 5, 2024 10:37 AM	4033e3a0
translate crunchbase fundingrounds	general
peers	general
news basic	general	Mar 5, 2024 10:37 AM	bb1924a8
events	markdown
bundesanzeiger	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
swot analysis	company_analysis
financial analysis	company_analysis
funding rounds analysis	company_analysis
company structure	company_analysis
purchaser profile	merger_acquisitions
private financials	financials
customer profile	customers

COM:EYEVENSYS

Eyevensys